HK Stock Movement | INNOVENT BIO (01801) Rises Nearly 3% in Late Trading as Company Prepares to Submit New Drug Application for Mazdutide 9mg for Adult Weight Control

Stock News

Nov 20, 2025

INNOVENT BIO (01801) saw a late-session surge of nearly 3%, closing up 2.62% at HK$92 with a turnover of HK$747 million. The company announced on November 20 that its Phase III clinical trial (GLORY-2) for Mazdutide Injection (IBI362) in Chinese adults with moderate-to-severe obesity met both primary and all key secondary endpoints. INNOVENT BIO plans to soon submit a new drug application for Mazdutide 9mg for adult weight control to regulatory authorities.

Mazdutide, co-developed by INNOVENT BIO and Eli Lilly, is a glucagon (GCG)/glucagon-like peptide-1 (GLP-1) dual receptor agonist—the first globally approved drug of its kind. It has already received approval in China for two indications: long-term weight management in adults with obesity or overweight, and blood sugar control in adults with type 2 diabetes.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1149437179"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1149437179\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1149437179?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-20 15:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1149437179","market":"sh","top_or_hot":-1,"title":"HK Stock Movement | INNOVENT BIO (01801) Rises Nearly 3% in Late Trading as Company Prepares to Submit New Drug Application for Mazdutide 9mg for Adult Weight Control","media":"Stock News","content":"<p>INNOVENT BIO (01801) saw a late-session surge of nearly 3%, closing up 2.62% at HK$92 with a turnover of HK$747 million. The company announced on November 20 that its Phase III clinical trial (GLORY-2) for Mazdutide Injection (IBI362) in Chinese adults with moderate-to-severe obesity met both primary and all key secondary endpoints. INNOVENT BIO plans to soon submit a new drug application for Mazdutide 9mg for adult weight control to regulatory authorities.</p>\n<p>Mazdutide, co-developed by INNOVENT BIO and Eli Lilly, is a glucagon (GCG)/glucagon-like peptide-1 (GLP-1) dual receptor agonist—the first globally approved drug of its kind. It has already received approval in China for two indications: long-term weight management in adults with obesity or overweight, and blood sugar control in adults with type 2 diabetes.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | INNOVENT BIO (01801) Rises Nearly 3% in Late Trading as Company Prepares to Submit New Drug Application for Mazdutide 9mg for Adult Weight Control</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | INNOVENT BIO (01801) Rises Nearly 3% in Late Trading as Company Prepares to Submit New Drug Application for Mazdutide 9mg for Adult Weight Control\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-20 15:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>INNOVENT BIO (01801) saw a late-session surge of nearly 3%, closing up 2.62% at HK$92 with a turnover of HK$747 million. The company announced on November 20 that its Phase III clinical trial (GLORY-2) for Mazdutide Injection (IBI362) in Chinese adults with moderate-to-severe obesity met both primary and all key secondary endpoints. INNOVENT BIO plans to soon submit a new drug application for Mazdutide 9mg for adult weight control to regulatory authorities.</p>\n<p>Mazdutide, co-developed by INNOVENT BIO and Eli Lilly, is a glucagon (GCG)/glucagon-like peptide-1 (GLP-1) dual receptor agonist—the first globally approved drug of its kind. It has already received approval in China for two indications: long-term weight management in adults with obesity or overweight, and blood sugar control in adults with type 2 diabetes.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2242644610.SGD","symbol_name":"Fidelity China Innovation A-ACC-SGD","start_time":0,"source_url":"","article_id":"1149437179","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1149437179","pubTimestamp":1763625292,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"INNOVENT BIO (01801) saw a late-session surge of nearly 3%, closing up 2.62% at HK$92 with a turnover of HK$747 million. The company announced on November 20 that its Phase III clinical trial...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK1583":"高瓴概念","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","BK1589":"北水核心资产","01801":"信达生物","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","BK1161":"生物科技","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC"},"translate_title":"港股动向|信达生物(01801)尾盘涨近3%公司准备提交用于成人体重控制的Mazdutide 9mg新药申请","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1},"content_text":"INNOVENT BIO (01801) saw a late-session surge of nearly 3%, closing up 2.62% at HK$92 with a turnover of HK$747 million. The company announced on November 20 that its Phase III clinical trial (GLORY-2) for Mazdutide Injection (IBI362) in Chinese adults with moderate-to-severe obesity met both primary and all key secondary endpoints. INNOVENT BIO plans to soon submit a new drug application for Mazdutide 9mg for adult weight control to regulatory authorities.\nMazdutide, co-developed by INNOVENT BIO and Eli Lilly, is a glucagon (GCG)/glucagon-like peptide-1 (GLP-1) dual receptor agonist—the first globally approved drug of its kind. It has already received approval in China for two indications: long-term weight management in adults with obesity or overweight, and blood sugar control in adults with type 2 diabetes.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}